Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
MLTX Analyst Ratings
Moderate Buy
10 Buy
5 Hold
2 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MLTX Stock 12 Month Forecast
Average Price Target
$15.38
▲(9.31% Upside)
| Highest Price Target$30.00 | Average Price Target$15.38 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Cantor Fitzgerald
―
Buy
―
Reiterated
12/04/25
H.C. Wainwright
$30→$26
Buy
84.79%
Upside
Reiterated
11/21/25
Goldman Sachs
$7→$8
Hold
-43.14%
Downside
Reiterated
11/07/25
Oppenheimer
$25→$30
Buy
113.22%
Upside
Reiterated
11/06/25
LifeSci Capital
$16
Buy
13.72%
Upside
Reiterated
11/05/25
MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments Drive Buy RatingThis morning, MoonLake (Nasdaq: MLTX) reported Q3 2025 earnings, finishing the quarter with $380.5M in cash, cash equivalents, and short-term marketable debt securies. The balance sheet along with funds from the non-diluve financing agreement with Hercules Capital are expected to fund operaons into H2 2027. The Company also announced a $75M underwrien offering which is expected to close on or about November 6 th . Recent updates from MoonLake’s pipeline include: Palmoplantar Pustulosis (PPP): PPP is a chronic skin disorder that is characterized by painful and recurrent pustules on the palms/soles and affects 10-15% of paents with psoriasis. Management notes that ~170k unique PPP paents were diagnosed in the US between 2016-2025, and~20k paents are newly diagnosed every year.
Needham
$20
Buy
42.15%
Upside
Reiterated
11/05/25
TD Cowen
―
Buy
―
Reiterated
11/05/25
MoonLake Immunotherapeutics: Promising Clinical Trials and Strategic Regulatory Advances Boost Confidence in Sonelokimab5:24 PM MoonLake Immunotherapeutics (NASDAQ: MLTX) Buy (1) ESG Target: NA Reports Q3; Type B Report THE TD COWEN INSIGHT MLTX reported a Q3 net loss of $70.7MM and 9/30 cash of $380.5MM. The Ph2 LEDA trial in PPP met its primary endpoint with 64% CfB in PPPASI at week 16, which is competitive and in our view supports the Ph3 initiation (Q3:26). In VELA OLE, HiSCRs continue to improve through week 40. MLTX will have Type B FDA meeting on Dec 15, and we look forward to clarity on SLK's path forward in HS. Remain Buy. Is A Of SLK in HS; FDA Type B Meeting Scheduled For Dec.
RBC Capital
$10
Hold
-28.93%
Downside
Reiterated
11/05/25
Wedbush
$18
Buy
27.93%
Upside
Reiterated
11/05/25
Citi
$5
Sell
-64.46%
Downside
Downgraded
10/29/25
Leerink Partners
$73→$14
Buy
-0.50%
Downside
Reiterated
10/01/25
Jefferies
$8
Hold
-43.14%
Downside
Downgraded
09/30/25
BTIG
―
Hold
―
Downgraded
09/29/25
Guggenheim
$80→$20
Buy
42.15%
Upside
Reiterated
09/29/25
Wolfe Research
―
Sell
―
Downgraded
09/29/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Cantor Fitzgerald
―
Buy
―
Reiterated
12/04/25
H.C. Wainwright
$30→$26
Buy
84.79%
Upside
Reiterated
11/21/25
Goldman Sachs
$7→$8
Hold
-43.14%
Downside
Reiterated
11/07/25
Oppenheimer
$25→$30
Buy
113.22%
Upside
Reiterated
11/06/25
LifeSci Capital
$16
Buy
13.72%
Upside
Reiterated
11/05/25
MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments Drive Buy RatingThis morning, MoonLake (Nasdaq: MLTX) reported Q3 2025 earnings, finishing the quarter with $380.5M in cash, cash equivalents, and short-term marketable debt securies. The balance sheet along with funds from the non-diluve financing agreement with Hercules Capital are expected to fund operaons into H2 2027. The Company also announced a $75M underwrien offering which is expected to close on or about November 6 th . Recent updates from MoonLake’s pipeline include: Palmoplantar Pustulosis (PPP): PPP is a chronic skin disorder that is characterized by painful and recurrent pustules on the palms/soles and affects 10-15% of paents with psoriasis. Management notes that ~170k unique PPP paents were diagnosed in the US between 2016-2025, and~20k paents are newly diagnosed every year.
Needham
$20
Buy
42.15%
Upside
Reiterated
11/05/25
TD Cowen
―
Buy
―
Reiterated
11/05/25
MoonLake Immunotherapeutics: Promising Clinical Trials and Strategic Regulatory Advances Boost Confidence in Sonelokimab5:24 PM MoonLake Immunotherapeutics (NASDAQ: MLTX) Buy (1) ESG Target: NA Reports Q3; Type B Report THE TD COWEN INSIGHT MLTX reported a Q3 net loss of $70.7MM and 9/30 cash of $380.5MM. The Ph2 LEDA trial in PPP met its primary endpoint with 64% CfB in PPPASI at week 16, which is competitive and in our view supports the Ph3 initiation (Q3:26). In VELA OLE, HiSCRs continue to improve through week 40. MLTX will have Type B FDA meeting on Dec 15, and we look forward to clarity on SLK's path forward in HS. Remain Buy. Is A Of SLK in HS; FDA Type B Meeting Scheduled For Dec.
RBC Capital
$10
Hold
-28.93%
Downside
Reiterated
11/05/25
Wedbush
$18
Buy
27.93%
Upside
Reiterated
11/05/25
Citi
$5
Sell
-64.46%
Downside
Downgraded
10/29/25
Leerink Partners
$73→$14
Buy
-0.50%
Downside
Reiterated
10/01/25
Jefferies
$8
Hold
-43.14%
Downside
Downgraded
09/30/25
BTIG
―
Hold
―
Downgraded
09/29/25
Guggenheim
$80→$20
Buy
42.15%
Upside
Reiterated
09/29/25
Wolfe Research
―
Sell
―
Downgraded
09/29/25
Best Analysts Covering MoonLake Immunotherapeutics
1 Month
xxx
Success Rate
16/26 ratings generated profit
Average Return
+13.14%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +13.14% per trade.
3 Months
xxx
Success Rate
17/26 ratings generated profit
Average Return
+30.32%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +30.32% per trade.
1 Year
Success Rate
9/17 ratings generated profit
Average Return
+11.98%
reiterated a buy rating last month
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +11.98% per trade.
2 Years
xxx
Success Rate
6/17 ratings generated profit
Average Return
-18.14%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 35.29% of your transactions generating a profit, with an average return of -18.14% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MLTX Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
8
8
10
14
9
Buy
13
14
10
3
2
Hold
1
5
5
7
3
Sell
0
1
2
2
1
Strong Sell
0
0
0
0
0
total
22
28
27
26
15
Each month's total comprises the sum of three months' worth of ratings.
MLTX Financial Forecast
MLTX Stock Forecast FAQ
What is MLTX’s average 12-month price target, according to analysts?
Based on analyst ratings, MoonLake Immunotherapeutics’s 12-month average price target is 15.38.
What is MLTX’s upside potential, based on the analysts’ average price target?
MoonLake Immunotherapeutics has 9.31% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MLTX a Buy, Sell or Hold?
MoonLake Immunotherapeutics has a consensus rating of Moderate Buy which is based on 10 buy ratings, 5 hold ratings and 2 sell ratings.
What is MoonLake Immunotherapeutics’s price target?
The average price target for MoonLake Immunotherapeutics is 15.38. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $5.00. The average price target represents 9.31% Increase from the current price of $14.07.
The highest analyst price target is $30.00 ,the lowest forecast is $5.00. The average price target represents 9.31% Increase from the current price of $14.07.
What do analysts say about MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of MLTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.